Every year on July 28, we mark World Hepatitis Day with an event to educate, gather together, and also remember those we have lost from the hepatitis C community. This year, we should have much to celebrate: in early 2017, medications that had previously been unavailable were finally added to some formularies, including Ontario’s. This means that people with certain types of hepatitis C who have been waiting years to access safe, effective medication will finally be able to start treatment and be cured. For many, being cured means avoiding potentially fatal outcomes like liver failure and liver cancer. It also means shedding the burden of carrying a highly stigmatized illness that is often met with ignorance, ostracism and discrimination.
People living with HIV in Canada have been charged with some of the most serious offences in the Criminal Code, even in cases of consensual sex where there was negligible or no risk of HIV transmission, no actual transmission and no intent to transmit.
The Undetectable=Untransmittable (“U=U”) campaign is based on scientific research, including the ground-breaking PARTNER study, establishing that when a person living with HIV on treatment maintains an undetectable viral load for at least six months, the risk of transmitting the virus through sex is effectively non-existent. As advocates for persons living with HIV await action from federal, provincial and territorial governments to address the overly-broad criminalization of HIV non-disclosure, how might the U=U campaign and the results of the PARTNER study impact ongoing prosecutions under the current state of the law?
At the opening of the recent 25th Harm Reduction International Conference in Montreal, the Minister of Health Jane Philpott announced that more people have died in the overdose epidemic in the past few years than died during the height of the AIDS crisis in the late 80s and early 90s. In 2016, it is estimated that 2,300 people died of overdose—preventable deaths caused by the prohibition of drugs.
In response to that sobering and sad announcement, we wrote an article asking for people engaged in the response to HIV to show support and solidarity with people who use drugs. We believe that making connections between the two epidemics can help build solidarity, increase public support and mobilize people into action to address the national overdose crisis. We wrote:
“People who have lived through the AIDS crisis, who work in HIV organizations, who call themselves allies of the HIV community, who have attended an HIV fundraiser, who have learned about the history of AIDS activism, we make an appeal to you: The time for you to step up and end the massive injustice taking place against people who use drugs is now. We need more resources. We need the government to take our solutions seriously. We need the overdose epidemic to be declared a national emergency. Help us do this.”
So what can you do if you want to show support and solidarity? Here are six things you and your organization can do:
Le Groupe d’étude canadien sur les soins de santé préventifs (GECSSP) a publié lundi ses Lignes directrices sur le dépistage du VHC dans le Journal de l’Association médicale canadienne (résumé disponible en français). À la consternation des experts partout au Canada, y compris des spécialistes de l’hépatite C, des groupes de défense des droits et d’autres intervenants, les nouvelles recommandations sur le dépistage ignorent les conseils d’experts en ce qui concerne le choix des candidats au dépistage de l’hépatite C, ce qui établit un précédent dangereux pour les politiques de santé publique, où les dollars ont préséance sur la santé des Canadiens.
Plus tôt cette année, la Colombie-Britannique, l’Alberta, la Saskatchewan, le Québec et l’Ontario ont annoncé un assouplissement des critères d’admissibilité à une couverture publique pour les médicaments anti-hépatite C qui sont en train de changer la vie des personnes atteintes, y compris Epclusa, Zepatier, daclatasvir et asunaprévir. Pour la première fois, ces médicaments seront accessibles aux personnes ayant des scores de fibrose plus bas (plus le score de fibrose est élevé, plus il y a de cicatrices dans le foie causées par la maladie, c’est-à-dire la cirrhose.)[i]
The emergence of PrEP has highlighted important gender inequalities in HIV transmission and HIV prevention. PrEP, or pre-exposure prophylaxis, is a drug that HIV-negative people (including women!) can take to help prevent HIV; however, most discussions about PrEP focus on men. Despite representing fewer new HIV infections than men, women also need innovative HIV prevention methods.
Le Blogue de CATIE présente des perspectives et opinions des personnes et organismes qui travaillent ou collaborent bénévolement à la réponse du Canada au VIH et à l’hépatite C.